ePocrates Inc.

In a crowded field of companies marketing web-based handheld devices that allow physicians to perform a myriad of functions, ePocrates Inc. is trying to differentiate itself by offering less than its competition. That is, its idea is to ease physicians into using web-enabled devices with a package of prescription drug information.

In a crowded field of companies marketing web-based handheld devices that allow physicians to perform a myriad of functions—from prescribing to ordering lab tests to checking for drug interactions—ePocrates Inc. is trying to differentiate itself by offering less than its competition. Perhaps more to the point, the company's management is initially producing a narrow set of easy-to-use applications that it hopes will attract a broad practitioner customer base to which it eventually hopes to sell more sophisticated features. The idea is to ease physicians, who have proven surprisingly resistant to incorporating Internet technologies in their practices, into using web-enabled devices with a package of prescription drug information (e.g., dosing, counterindications, adverse reactions) that can readily be accessed at the point-of-care.

Major e-health companies like WebMDCorp.have learned the hard way that the single biggest barrier to creating the proverbial "seamless web"...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By 

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

More from Business

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By 

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By 

Series B cash will be used to advance its Stargardt disease gene therapy.